This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Martindale Pharma, the UK based leading international specialty pharma company announced a new licensing agreement with its strategic partner Unimedic AB for its Emergency Care sterile ampoule products in Sweden, Denmark, Norway and Finland.
Under the new agreement, Unimedic AB will launch three undisclosed products. This builds on the long term relationship between the companies in Scandinavia which has seen Unimedic AB successfully commercialise a Martindale Pharma adrenaline ampoule product in Sweden. Financial terms of the agreement were not disclosed. The Companies will work together on regulatory and supply chain activities leading to the launch of the products.
Unimedic AB is the lead commercialisation partner in Scandinavia for Martindale Pharma. In addition to the Emergency Care portfolio, Unimedic AB is working with Martindale Pharma commercialising its opioid addiction portfolio in the region.
Michael Harris, Chief Executive Officer, commented: “Scandinavia is an area of focus for Martindale Pharma’s international growth plans. We are pleased to extend our partnership with Unimedic AB, providing further opportunity to launch our products into additional markets. We intend to add additional products from our Emergency Care range to the licensing agreement we have with Unimedic in the next few months”.
